Multiple T-cell and immune cell surface antigens (CD50, CD52, CD54, HLA class I, HLA-DR, β2-microglobulin) (ATG targets)

The target Multiple T-cell and immune cell surface antigens refers to a broad array of proteins found on the surface of lymphocytes and other immune cells, specifically including adhesion molecules (CD50, CD54), the lymphocyte-depletion marker CD52, and major histocompatibility complex (MHC) proteins (HLA class I, HLA-DR, and β2-microglobulin). These antigens play critical roles in immune cell adhesion, signaling, and antigen presentation. This multi-antigen profile is the primary target of polyclonal antithymocyte globulin (ATG) preparations, such as rabbit-derived Thymoglobulin and equine-derived Atgam. By binding to these diverse markers, ATG induces rapid and profound depletion of circulating T-cells through mechanisms such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and the induction of apoptosis. Clinically, targeting this group of antigens is essential for preventing and treating acute rejection in organ transplantation and managing graft-versus-host disease (GVHD) in stem cell transplantation. Additionally, it is used in the management of severe aplastic anemia to suppress the autoimmune destruction of bone marrow. The broad spectrum of activity ensures comprehensive immunosuppression but also necessitates careful monitoring for safety concerns like cytokine release syndrome and increased infection risk.

Other names

Antithymocyte globulin targetsThymoglobulin targetsAtgam targetsAnti-lymphocyte globulin targetsATG targets

Polyclonal antibody-mediated depletion of T-cells and other immune cells via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and induction of apoptosis.